新发转移性乳腺癌患者的新型预后分期系统
研究基于美国国家癌症数据库(NCDB)2010-2016年新发转移性乳腺癌(dnMBC)患者,利用递归 partitioning 分析按临床T分期、分级、ER、PR、HER2、组织学、转移器官系统及受累器官系统数分组,以3年总生存率划分IVA至IVD四期,并在SEER和NCDB独立队列中验证。
要点
- 基于NCDB的大样本dnMBC患者数据,用递归 partitioning 分析建立预后分期系统。
- 新分期将患者分为IVA(3年OS 73.2%)、IVB(61.9%)、IVC(40.1%)、IVD(17%),四期间OS差异显著(log-rank P < .001)。
- 该分期系统在SEER和NCDB独立队列中验证,四期生存差异均显著(log-rank P < .001)。
核心结论
- dnMBC患者结局的异质性研究结果可能为未来修订美国癌症联合委员会(AJCC)新诊断IV期分期指南提供参考。
- 研究结果需独立确认。
研究设计与样本
- 从美国国家癌症数据库(NCDB)筛选2010-2016年新发转移性乳腺癌(dnMBC)患者。
- 采用递归 partitioning 分析(RPA)根据临床T分期、分级、雌激素受体(ER)、孕激素受体、人表皮生长因子受体2、组织学、转移器官系统部位(仅骨、仅脑、内脏)及受累器官系统数进行分组。
- 以3年总生存(OS)率划分最终分期:IVA >70%,IVB 50%-70%,IVC 25%至<50%,IVD <25%。
- 采用1,000次迭代的自助法(bootstrapping),根据最常出现的赋值确定最终分期。
- 使用SEER和NCDB数据进行验证分析。
主要发现
- 原始队列中位OS为35.4个月(95% CI,34.8至35.9)。
- RPA将患者分为53组,3年OS率范围为73.5%至5.7%。
- 53组合并为四个分期组:3年OS率A组 = 73.2%,B组 = 61.9%,C组 = 40.1%,D组 = 17%(log-rank P < .001)。
- 自助法后四期生存结局仍差异显著(log-rank P < .001)。
- 验证队列中SEER数据(N = 20,469)和NCDB另一队列(N = 7,645)四期生存差异均显著(log-rank P < .001)。
关键数值与推荐
- 最终分期依据3年OS率:IVA >70%,IVB 50%-70%,IVC 25%至<50%,IVD <25%。
- 原始队列N = 42,467,中位随访52.9个月,中位OS 35.4个月(95% CI,34.8至35.9)。
- RPA分组3年OS率范围73.5%至5.7%。
- 合并后四期3年OS率:A组73.2%,B组61.9%,C组40.1%,D组17%(log-rank P < .001)。
- 验证队列:SEER N = 20,469,NCDB另一队列N = 7,645,四期生存差异均log-rank P < .001。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文指出研究结果需独立确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Given the heterogeneity and improvement in outcomes for metastatic breast cancer (MBC), we developed a staging system that refines prognostic estimates for patients with metastatic cancer at the time of initial diagnosis, de novo MBC (dnMBC), on the basis of survival outcomes and disease-related variables. METHODS: Patients with dnMBC (2010-2016) were selected from the National Cancer Database (NCDB). Recursive partitioning analysis (RPA) was used to group patients with similar overall survival (OS) on the basis of clinical T category, grade, estrogen receptor (ER), progesterone receptor, human epidermal growth factor receptor 2, histology, organ system site of metastases (bone-only, brain-only, visceral), and number of organ systems involved. Three-year OS rates were used to assign a final stage: IVA: >70%, IVB: 50%-70%, IVC: 25 to <50%, and IVD: <25%. Bootstrapping was applied with 1,000 iterations, and final stage assignments were made based on the most commonly occurring assignment. Unadjusted OS was estimated. Validation analyses were conducted using SEER and NCDB. RESULTS: At a median follow-up of 52.9 months, the median OS of the original cohort (N = 42,467) was 35.4 months (95% CI, 34.8 to 35.9). RPA stratified patients into 53 groups with 3-year OS rates ranging from 73.5% to 5.7%; these groups were amalgamated into four stage groups: 3-year OS, A = 73.2%, B = 61.9%, C = 40.1%, and D = 17% (log-rank P < .001). After bootstrapping, the survival outcomes for the four stages remained significantly different (log-rank P < .001). This staging system was then validated using SEER data (N = 20,469) and a separate cohort from the NCDB (N = 7,645) (both log-rank P < .001). CONCLUSION: Our findings regarding the heterogeneity in outcomes for patients with dnMBC could guide future revisions of the current American Joint Committee on Cancer staging guidelines for patients with newly diagnosed stage IV disease. Our findings should be independently confirmed.
引用
- Plichta JK, Thomas SM, Hayes DF, et al. Novel Prognostic Staging System for Patients With De Novo Metastatic Breast Cancer. J Clin Oncol. 2023. PMID: 36944149. doi:10.1200/JCO.22.02222
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。